a200-0700
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2024 (NCT06846567)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CACNA2D1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCC1=C[C@@H]2[C@H](C1)C[C@]2(CN)CC(=O)O- Mol. weight
- 209.29 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545125 ↗
Also known as
- a200-0700
- a200-0700
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06846567 | Phase 1 | Dec 1, 2024 | Government of China |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 1 | 1 | 1 | 2024 |
1 organizations
Page 1 / 1